An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
HeartBeam to Host Third Quarter 2022 Results Conference Call on Thursday November 10, 2022 at 4:30 p.m. Eastern Time
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT), a leader in cardiac technology, will hold a conference call on November 10, 2022, at 4:30 p.m. Eastern time to discuss its Q3 results for the period ending September 30, 2022. CEO Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will lead the call, reviewing recent announcements and future milestones. A press release detailing results will precede the call. Investors can access the call via dial-in or webcast, and a replay will be available until February 10, 2023.
Positive
None.
Negative
None.
SANTA CLARA, Calif.--(BUSINESS WIRE)--
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, will hold a conference call on Thursday November 10, 2022 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2022, and will be reviewing recent announcements, ongoing initiatives, and key 2022 and anticipated 2023 milestones. A press release detailing these results will be issued prior to the call.
HeartBeam CEO and Founder Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company’s website here.
To access the call, please use the following information:
A telephone replay will be available approximately two hours after the call and will run through February 10, 2023, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 7787050. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the company’s investor relations section here.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI™ is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo™ is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies. For more information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our in our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
The HeartBeam conference call is scheduled for November 10, 2022, at 4:30 p.m. Eastern time.
What will be discussed during the HeartBeam conference call?
The conference call will discuss HeartBeam's Q3 results for the period ending September 30, 2022, along with recent announcements and future milestones.
Who are the speakers for HeartBeam's upcoming conference call?
HeartBeam's conference call will be led by CEO Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD.
How can I access the HeartBeam conference call?
You can access the HeartBeam conference call by dialing 1-800-458-4121 (U.S.) or 1-646-828-8193 (International) or by using the webcast link provided in the press release.
Will there be a replay of the HeartBeam conference call?
Yes, a replay of the HeartBeam conference call will be available from approximately two hours after the call until February 10, 2023.
What products is HeartBeam developing?
HeartBeam is developing two patented products: HeartBeam AIMI for acute care settings and HeartBeam AIMIGo, a credit card-sized ECG device.
